ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
AbbVie Exercises Right to Acquire TeneoOne and TNB-383B for the Potential Treatment of Relapsed or Refractory Multiple Myeloma
June 25, 2021AbbVie and Teneobio, Inc. announced that AbbVie exercised its exclusive right to acquire TeneoOne, an affiliate of Teneobio, Inc., and TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of relapsed or refractory multiple myeloma ...
Pharma Sources Insight January 2025
